×
About 1,030 results

ALLMedicine™ Adult T-cell Leukemia/lymphoma Center

Research & Reviews  368 results

An Open-Label, Single-Arm, Phase 2 Trial of Valemetostat in Relapsed or Refractory Adul...
https://doi.org/10.1182/blood.2022016862
Blood Izutsu K, Makita S et. al.

Sep 24th, 2022 - Adult T-cell leukemia/lymphoma (ATL) is an aggressive non-Hodgkin lymphoma with poor prognosis and few treatment options for patients with relapsed, recurrent, or refractory disease. We evaluated the efficacy and safety of valemetostat, a potent E...

Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT04639843

Sep 23rd, 2022 - Background: T-cell lymphomas (TCLs) are a heterogeneous group of lymphoid malignancies defined by clonal proliferation of post-thymic T lymphocytes. Patients with newly diagnosed TCLs are most commonly treated with a CHOP (cyclophosphamide, doxoru...

Tissue Collection for Studies of Lymph Cancer
https://clinicaltrials.gov/ct2/show/NCT01676805

Sep 19th, 2022 - Background: An estimated 79,190 people living in the United States will be diagnosed with lymphoma in 2012, including 9,060 cases of HL, 70,130 cases of non-Hodgkin s lymphoma (NHL) and multiple cases of adult T-cell leukemia/lymphoma. Laboratory ...

Molecular insight into the study of adult T-cell leukemia/lymphoma (ATLL): Ten-year stu...
https://doi.org/10.1016/j.gene.2022.146885
Gene Ashrafi F, Rahimzada M et. al.

Sep 16th, 2022 - The outcome of successful infection, including human T-cell leukemia virus type 1 (HTLV-1), is determined by the interactions between the host and the infectious agent. Ten years of work on HTLV-1-associated diseases in an endemic region of Iran h...

Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies
https://clinicaltrials.gov/ct2/show/NCT03905135

Sep 13th, 2022 - Background: Mature T-cell cancers are a phenotypically heterogeneous group of malignancies which constitute 10-15% of all non-Hodgkin lymphomas (NHL). Patients with relapsed/refractory T cell lymphomas have limited therapeutic options, making new ...

see more →

Drugs  1 results see all →

Clinicaltrials.gov  18 results

Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT04639843

Sep 23rd, 2022 - Background: T-cell lymphomas (TCLs) are a heterogeneous group of lymphoid malignancies defined by clonal proliferation of post-thymic T lymphocytes. Patients with newly diagnosed TCLs are most commonly treated with a CHOP (cyclophosphamide, doxoru...

Tissue Collection for Studies of Lymph Cancer
https://clinicaltrials.gov/ct2/show/NCT01676805

Sep 19th, 2022 - Background: An estimated 79,190 people living in the United States will be diagnosed with lymphoma in 2012, including 9,060 cases of HL, 70,130 cases of non-Hodgkin s lymphoma (NHL) and multiple cases of adult T-cell leukemia/lymphoma. Laboratory ...

Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies
https://clinicaltrials.gov/ct2/show/NCT03905135

Sep 13th, 2022 - Background: Mature T-cell cancers are a phenotypically heterogeneous group of malignancies which constitute 10-15% of all non-Hodgkin lymphomas (NHL). Patients with relapsed/refractory T cell lymphomas have limited therapeutic options, making new ...

Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)
https://clinicaltrials.gov/ct2/show/NCT04703192

Sep 7th, 2022 - This study was designed to evaluate the efficacy and safety of valemetostat tosylate monotherapy. The primary objective will evaluate objective response rate of valemetostat tosylate monotherapy as measured by blinded independent central review (B...

Study of Lacutamab in Peripheral T-cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT04984837

Aug 19th, 2022 - This is an open-label multicenter randomized non comparative phase II study to evaluate the safety and efficacy of the monoclonal anti-KIR3DL2 antibody Lacutamab in patients with Refractory/Relapsing (R/R) KIR3DL2 positive Peripheral T Cell Lympho...

see more →

News  25 results

An International Experience at Home
https://www.onclive.com/view/an-international-experience-at-home

Dec 5th, 2020 - Christopher Dittus, DO, MPH I often find myself in awe of physicians who travel around the world seeking out the 2 most desirable aspects of medicine—patients in desperate need of medical care and patients with genuinely novel pathology. The dow...

NCCN Guidelines Reflect Recent FDA Approvals for Hematologic Malignancies
https://www.onclive.com/view/nccn-guidelines-reflect-recent-fda-approvals-for-hematologic-malignancies

Dec 5th, 2020 - Meletios A. Dimopoulos, MD New options for patients with hematologic malignancies stemming from recent FDA approvals are making an impact on treatment strategies recommended in the National Comprehensive Cancer Network (NCCN) Clinical Practice Gu...

Targeted Agents Lead Treatment Advances in T-Cell Lymphoma
https://www.onclive.com/view/targeted-agents-lead-treatment-advances-in-t-cell-lymphoma

Dec 4th, 2020 - Jasmine M. Zain, MD Results from the phase III ECHELON-2 trial set a precedent for targeted therapy in T-cell lymphoma by showing the benefit of adding brentuximab vedotin (Adcetris) to standard chemotherapy in patients with advanced CD30-express...

Systemic Epstein-Barr Virus–Positive T-cell Lymphoma of Childhood
https://www.mdedge.com/dermatology/article/211566/pediatrics/systemic-epstein-barr-virus-positive-t-cell-lymphoma-childhood/page/0/2?channel=45

Nov 5th, 2019 - Comment Prevalence and Presentation Epstein-Barr virus is a ubiquitous γ-herpesvirus with tropism for B cells, affecting more than 90% of the adult population worldwide. In addition to infecting B cells, EBV is capable of infecting T and NK cells,.

Cobomarsen shows early promise for treating ATLL
https://www.mdedge.com/hematology-oncology/article/194089/lymphoma-plasma-cell-disorders/cobomarsen-shows-early-promise
Jennifer Smith

Feb 7th, 2019 - LA JOLLA, CALIF. – Phase 1 results suggest cobomarsen is well tolerated and can maintain or improve responses in patients with previously treated adult T-cell leukemia/lymphoma (ATLL).

see more →